Literature DB >> 16402319

[Topiramate and epilepsy in the light of Das-Naglieri Cognitive Assessment System].

F Pérez-Alvarez1, C Timoneda-Gallart, J Baus-Rosell.   

Abstract

INTRODUCTION: Cognitive side effect is a possible effect of topiramate. Cognitive function is not unanimously defined and a test measures according to the concept is based on. On the other hand, behavioral dysfunction is frequent in epileptics and the euthimic effect of topiramate on impulsive dysfunction is known. AIMS: To asses the cognitive effect of topiramate with a modern battery, Das-Naglieri Cognitive Assessment System (DN:CAS), which diagnoses mental programs, but not only achievement. Also, to test the influence of topiramate on behavior. PATIENTS AND METHODS: As a prospective study, 35 patients with idiopathic or cryptogenic epilepsies were administered DN:CAS battery, and, simultaneously, patients and parents were given behavioral questionnaires at baseline, and after 6 and 12 months on topiramate. Cognitive scores were compared to those of a group of healthy controls at baseline, and baseline scores were compared to 6 and 12 months follow-up scores within the patient group. t-Student was applied.
RESULTS: Patient scores were lower in successive processing before treatment as compared to controls (p < 0.001). After 6 months no change was noted. After 12 months of treatment, patients scored significantly better in planning processing than before treatment (p = 0.04) and, moreover, improved behavioral scores were noted.
CONCLUSIONS: The patients showed a successive processing dysfunction not related with topiramate. An improved planning processing and behavioral pattern were observed 12 months after treatment. According to the euthimic effect of topiramate and the neurocognitive-neuroimpulsive interaction, a positive effect of topiramate on DN:CAS cognition and behavior can be postulated.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16402319

Source DB:  PubMed          Journal:  Rev Neurol        ISSN: 0210-0010            Impact factor:   0.870


  2 in total

1.  Tolerability and safety of topiramate in Chinese patients with epilepsy : an open-label, long-term, prospective study.

Authors:  Yang Lu; Xuefeng Wang; Qihua Li; Jingmei Li; Yong Yan
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

2.  A review and empirical study of the composite scales of the Das-Naglieri cognitive assessment system.

Authors:  Simon M McCrea
Journal:  Psychol Res Behav Manag       Date:  2009-03-18
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.